Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 19/20 | 0.46 |
| ▸ | KDR | P35968 | 17/20 | 0.46 |
| ▸ | MST1R | Q04912 | 6/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | FPR1 | P21462 | 1/20 | 0.42 |
| ▸ | FPR3 | P25089 | 1/20 | 0.42 |
| ▸ | GPR183 | P32249 | 1/20 | 0.42 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12252005 | 0.88 | MET (0.44) | METKDRMST1R | |
| SCHEMBL12252014 | 0.85 | MET (0.42) | METKDRMST1R | |
| SCHEMBL2534843 | 0.85 | MET (0.45) | METKDRMST1R | |
| SCHEMBL10202157 | 0.85 | MET (0.42) | METKDRMST1R | |
| SCHEMBL12252011 | 0.82 | MST1R (0.47) | METKDRMST1R | |
| SCHEMBL13185462 | 0.81 | MET (0.57) | METKDRMST1R | |
| SCHEMBL10202158 | 0.80 | MET (0.40) | METKDRMST1R | |
| SCHEMBL3565411 | 0.80 | MET (0.46) | METKDRMST1R | |
| SCHEMBL12245366 | 0.79 | MET (0.48) | METKDRMST1R | |
| SCHEMBL12252008 | 0.79 | MST1R (0.45) | METKDRMST1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2011-10-20 | — | — | US | disclosed |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | ERBB2, ABL1, FLT1 | MET 138/4885KDR 5/4885MST1R 150/4885 |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | ABL1, ERBB2, TYRO3 | MET 111/4885KDR 8/4885MST1R 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.